CU20160152A7 - Nuevos compuestos macrocíclicos en calidad de inhibidores de cdk9, un proceso para su preparación y los compuestos intermediarios útiles en la preparación de estos compuestos - Google Patents

Nuevos compuestos macrocíclicos en calidad de inhibidores de cdk9, un proceso para su preparación y los compuestos intermediarios útiles en la preparación de estos compuestos

Info

Publication number
CU20160152A7
CU20160152A7 CUP2016000152A CU20160152A CU20160152A7 CU 20160152 A7 CU20160152 A7 CU 20160152A7 CU P2016000152 A CUP2016000152 A CU P2016000152A CU 20160152 A CU20160152 A CU 20160152A CU 20160152 A7 CU20160152 A7 CU 20160152A7
Authority
CU
Cuba
Prior art keywords
compounds
preparation
quality
useful intermediate
new macrocyclic
Prior art date
Application number
CUP2016000152A
Other languages
English (en)
Other versions
CU24399B1 (es
Inventor
Ulrich Lücking
Pierre Wasnaire
Arne Scholz
Philip Lienau
Gerhard Siemeister
Christian Stegmann
Ulf Bömer
Kunzeng Zheng
Ping Gao
Gang Chen
Jiajun Xi
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52824234&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU20160152(A7) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of CU20160152A7 publication Critical patent/CU20160152A7/es
Publication of CU24399B1 publication Critical patent/CU24399B1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/15—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen
    • C07C53/16—Halogenated acetic acids
    • C07C53/18—Halogenated acetic acids containing fluorine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)

Abstract

Nuevos compuestos macrocíclicos de la fórmula general (I) como se los describe y se los define en la memoria descriptiva. Métodos para prepararlos. Su uso en el tratamiento y/o la profilaxis de diversos trastornos, particularmente de los trastornos hiperproliferativos, de las enfermedades infecciosas inducidas por virus y/o de las enfermedades cardiovasculares. Compuestos intermedios útiles para preparar los compuestos de la fórmula general (I).
CU2016000152A 2014-04-11 2015-04-08 Nuevos compuestos macrocíclicos en calidad de inhibidores de cdk9, un proceso para su preparación y los compuestos intermediarios útiles en la preparación de estos compuestos CU24399B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2014000392 2014-04-11
PCT/EP2015/057546 WO2015155197A1 (en) 2014-04-11 2015-04-08 Novel macrocyclic compounds

Publications (2)

Publication Number Publication Date
CU20160152A7 true CU20160152A7 (es) 2017-04-05
CU24399B1 CU24399B1 (es) 2019-04-04

Family

ID=52824234

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2016000152A CU24399B1 (es) 2014-04-11 2015-04-08 Nuevos compuestos macrocíclicos en calidad de inhibidores de cdk9, un proceso para su preparación y los compuestos intermediarios útiles en la preparación de estos compuestos

Country Status (28)

Country Link
US (1) US9963464B2 (es)
EP (1) EP3129387B1 (es)
JP (1) JP6605493B2 (es)
KR (1) KR102383938B1 (es)
CN (1) CN106459084B (es)
AP (1) AP2016009483A0 (es)
AR (1) AR099999A1 (es)
AU (1) AU2015243585B2 (es)
BR (1) BR112016023554B1 (es)
CA (1) CA2945237C (es)
CL (1) CL2016002577A1 (es)
CR (1) CR20160471A (es)
CU (1) CU24399B1 (es)
DO (1) DOP2016000278A (es)
EA (1) EA032541B1 (es)
ES (1) ES2743799T3 (es)
IL (1) IL247966B (es)
MX (1) MX2016013362A (es)
PE (1) PE20161379A1 (es)
PH (1) PH12016501968A1 (es)
SG (1) SG11201608430RA (es)
SV (1) SV2016005301A (es)
TN (1) TN2016000435A1 (es)
TW (1) TW201623312A (es)
UA (1) UA119349C2 (es)
UY (1) UY36072A (es)
WO (1) WO2015155197A1 (es)
ZA (1) ZA201607765B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108290903B (zh) * 2015-09-29 2021-09-03 拜耳医药股份有限公司 新的大环磺酰二亚胺化合物
CN108368129B (zh) * 2015-10-08 2021-08-17 拜耳医药股份有限公司 改性大环化合物
PT3445767T (pt) * 2016-04-22 2020-05-13 Astrazeneca Ab Inibidores de mcl-1 macrocíclicos para o tratamento de cancro
RU2019111887A (ru) * 2016-10-20 2020-11-20 Пфайзер Инк. Антипролиферативные средства для лечения лаг
US11242356B2 (en) 2017-03-28 2022-02-08 Bayer Aktiengesellschaft PTEFb inhibiting macrocyclic compounds
PL3601253T3 (pl) 2017-03-28 2022-01-17 Bayer Aktiengesellschaft Nowe hamujące ptefb związki makrocykliczne
CN109251212A (zh) * 2017-07-14 2019-01-22 上海长森药业有限公司 内环硫醚酰胺-芳基酰胺类化合物及其治疗乙型肝炎的用途
CN111434665B (zh) * 2019-01-11 2023-03-10 上海长森药业有限公司 内环硫脒酰胺-芳基酰胺类化合物及其治疗乙型肝炎的用途
CN112321604A (zh) * 2019-08-05 2021-02-05 华东理工大学 大环类jak2抑制剂及其应用
WO2023057812A1 (en) 2021-10-04 2023-04-13 Vincerx Pharma Gmbh Compounds, pharmaceutical compositions, and methods for the treatment, prevention, or management of hyperproliferative disorder

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2556946T3 (es) 2000-12-21 2016-01-21 Novartis Ag Pirimidinaminas como moduladores de la angiogénesis
DE10239042A1 (de) * 2002-08-21 2004-03-04 Schering Ag Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel
DE10349423A1 (de) 2003-10-16 2005-06-16 Schering Ag Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
KR20070091018A (ko) 2004-12-17 2007-09-06 아스트라제네카 아베 Ｃｄｋ 억제제로서의4-(4-(이미다졸-4-일)피리미딘-2-일아미노)벤즈아미드
DE102006042143A1 (de) 2006-09-08 2008-03-27 Bayer Healthcare Aktiengesellschaft Neue substituierte Bipyridin-Derivate und ihre Verwendung
WO2008060248A1 (en) 2006-11-15 2008-05-22 S*Bio Pte Ltd. Indole sustituted pyrimidines and use thereof in the treatment of cancer
KR20090101905A (ko) 2006-12-22 2009-09-29 노파르티스 아게 인돌-４-일-피리미디닐-일-아민 유도체 및 사이클린 의존성 키나제 억제제로서의 그의 용도
CA2672518A1 (en) 2006-12-22 2008-07-03 Novartis Ag Organic compounds and their uses
JP5566880B2 (ja) 2007-04-24 2014-08-06 インゲニウム ファーマシューティカルズ ジーエムビーエイチ プロテインキナーゼの阻害剤としての４，６−二置換アミノピリミジン誘導体
JP5379787B2 (ja) 2007-04-24 2013-12-25 インゲニウム ファーマシューティカルズ ジーエムビーエイチ プロテインキナーゼの阻害剤
ES2539518T3 (es) 2007-04-24 2015-07-01 Astrazeneca Ab Inhibidores de proteínas quinasas
WO2008132138A1 (en) 2007-04-25 2008-11-06 Ingenium Pharmaceuticals Gmbh Derivatives of 4,6-disubstituted aminopyrimidines
WO2009029998A1 (en) 2007-09-06 2009-03-12 Cytopia Research Pty Ltd Retrometabolic compounds
GB0805477D0 (en) 2008-03-26 2008-04-30 Univ Nottingham Pyrimidines triazines and their use as pharmaceutical agents
US8415381B2 (en) 2009-07-30 2013-04-09 Novartis Ag Heteroaryl compounds and their uses
AU2011231975B2 (en) 2010-03-22 2014-07-03 Bayer Intellectual Property Gmbh Pharmaceutically active disubstituted triazine derivatives
CN103562184B (zh) 2011-03-02 2016-04-27 利德探索中心有限公司 药学活性的二取代的吡啶衍生物
EP2527332A1 (en) 2011-05-24 2012-11-28 Bayer Intellectual Property GmbH 4-Aryl-N-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group as CDK9 inhibitors
JP5976814B2 (ja) 2011-09-16 2016-08-24 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ スルホキシイミン基を含有する二置換５−フルオロピリミジン誘導体
WO2013037896A1 (en) * 2011-09-16 2013-03-21 Bayer Intellectual Property Gmbh Disubstituted 5-fluoro-pyrimidines
CN105102434A (zh) 2012-10-18 2015-11-25 拜耳药业股份公司 含砜基团的4-(邻)-氟苯基-5-氟嘧啶-2-基胺
CN104918918B (zh) 2012-11-15 2017-10-24 拜耳药业股份公司 含磺亚胺基团的4‑(邻)‑氟苯基‑5‑氟嘧啶‑2‑基胺
LT2928878T (lt) 2012-11-15 2016-11-25 Bayer Pharma Aktiengesellschaft 5-fluor-n-(piridin-2-il)piridin-2-amino dariniai, turintys sulfoksimino grupę
WO2015001021A1 (en) 2013-07-04 2015-01-08 Bayer Pharma Aktiengesellschaft Sulfoximine substituted 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives and their use as cdk9 kinase inhibitors
US9856242B2 (en) 2014-03-13 2018-01-02 Bayer Pharma Aktiengesellscaft 5-fluoro-N-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfone group

Also Published As

Publication number Publication date
EP3129387B1 (en) 2019-06-26
UA119349C2 (uk) 2019-06-10
AU2015243585B2 (en) 2019-08-01
CR20160471A (es) 2016-12-21
CA2945237C (en) 2022-09-06
KR20160136449A (ko) 2016-11-29
UY36072A (es) 2015-11-30
CA2945237A1 (en) 2015-10-15
WO2015155197A1 (en) 2015-10-15
ZA201607765B (en) 2022-09-28
MX2016013362A (es) 2017-02-09
CL2016002577A1 (es) 2017-04-07
CN106459084A (zh) 2017-02-22
JP2017510598A (ja) 2017-04-13
EA032541B1 (ru) 2019-06-28
AU2015243585A1 (en) 2016-10-13
AR099999A1 (es) 2016-08-31
CU24399B1 (es) 2019-04-04
SG11201608430RA (en) 2016-11-29
BR112016023554A2 (pt) 2017-08-15
PH12016501968A1 (en) 2016-12-19
KR102383938B1 (ko) 2022-04-08
TW201623312A (zh) 2016-07-01
ES2743799T3 (es) 2020-02-20
PE20161379A1 (es) 2017-01-15
BR112016023554B1 (pt) 2023-03-14
US9963464B2 (en) 2018-05-08
TN2016000435A1 (en) 2018-04-04
US20170029439A1 (en) 2017-02-02
IL247966B (en) 2021-02-28
JP6605493B2 (ja) 2019-11-13
AP2016009483A0 (en) 2016-10-31
DOP2016000278A (es) 2016-11-15
SV2016005301A (es) 2018-03-12
EA201692034A1 (ru) 2017-04-28
CN106459084B (zh) 2019-04-19
EP3129387A1 (en) 2017-02-15
IL247966A0 (en) 2016-11-30

Similar Documents

Publication Publication Date Title
CU20160152A7 (es) Nuevos compuestos macrocíclicos en calidad de inhibidores de cdk9, un proceso para su preparación y los compuestos intermediarios útiles en la preparación de estos compuestos
CU20150052A7 (es) Derivados de 5-fluoro-n-(piridin-2-il)piridin-2-amina que contienen un grupo sulfoximina
NI201700096A (es) Derivados de 4h-pirrol[3, 2-c]piridin-4-ona
CU20130157A7 (es) 4 - aril- n- fenil- 1,3,5- triazin- 2- aminas que contienen un grupo sulfoximina
GT201700189A (es) Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos
CL2017000712A1 (es) Pirimidinonas como inhibidores del factor xia
CL2018000039A1 (es) Derivados de oxopiridina sustituidos
CL2016001963A1 (es) Heteroarilos inhibidores de syk
EA201790630A1 (ru) Способы получения рибозидов
ECSP13013021A (es) Compuestos de benzotiazol y su uso farmacéutico
EA201790266A1 (ru) Индолы для применения при инфекции, вызванной вирусом гриппа
DOP2015000117A (es) Derivados de n-(piridin-2-il)pirimidin-4-amina que contienen un grupo sulfoximina
ECSP18074962A (es) Derivados de aminotiazol útiles como agentes antivíricos
UY36938A (es) Nuevos compuestos macrocíclicos modificados
UY36070A (es) Triterpenoides con actividad inhibidora de la maduración de hiv
UY36923A (es) Nuevos compuestos macrocíclicos de sulfondiimina
CR20160016A (es) Pirazolpiridinas sustituidas
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
CY1120185T1 (el) Υποκατεστημενα πυριδινικα παραγωγα χρησιμα ως αναστολεις c-fms κινασης
CL2017000707A1 (es) Derivados de nucleosidos sustituidos de 4'-vinilo como inhibidores de la replicación del arn del virus sincicial respiratorio
SV2016005282A (es) Nuevos compuestos
UY36284A (es) Método para la preparación de imidazopiridazinas sustituidas